CN112080482B - 一种Taq DNA聚合酶突变体Mut2及其应用 - Google Patents
一种Taq DNA聚合酶突变体Mut2及其应用 Download PDFInfo
- Publication number
- CN112080482B CN112080482B CN202010982425.2A CN202010982425A CN112080482B CN 112080482 B CN112080482 B CN 112080482B CN 202010982425 A CN202010982425 A CN 202010982425A CN 112080482 B CN112080482 B CN 112080482B
- Authority
- CN
- China
- Prior art keywords
- leu
- ala
- glu
- arg
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/10—Nucleotidyl transfering
- C12Q2521/101—DNA polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/125—Electrophoretic separation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
Abstract
本发明公开Taq DNA聚合酶突变体Mut2及其应用，所述突变型Taq DNA聚合酶在SEQ ID NO.1所示的序列中，具有下述的一个或多个氨基酸位置上的氨基酸取代，各取代用三联体表示：字母‑数字‑字母，其中数字表示突变氨基酸的位置，数字前的字母对应突变涉及的氨基酸，数字后的字母表示用于置换数字前氨基酸的氨基酸：T386A，A407L，F413Y。本发明所述的突变体，可以通过改变酶的构象，提高酶的耐受能力，很好的应用于血液样本的扩增。
Description
本申请为申请日为2019年10月29日，申请号为201911038688.1，发明名称为一种Taq DNA聚合酶突变体及其应用的中国发明专利的分案申请。
技术领域
本发明涉及生物技术领域，具体涉及一种Taq DNA聚合酶突变体Mut2及其应用。
背景技术
PCR技术己广泛应用于遗传病分子诊断、动植物进出口检疫、临床检验、食品安全监测、亲子鉴定和土壤微生物检测等众多领域。检测的基因模板主要来自从组织、唾液、细胞、痰液、血液、便以及土壤等。血液、土壤等样本中因为还有血红蛋白、血红素、乳铁蛋白、IgG和腐殖酸等，这些物质都对Taq DNA聚合酶有很强的抑制作用。传统的方法是从这些样本中将核酸提取出来，再进行PCR扩增。由于该领域的检测通量越来越大，传统的方法操作步骤繁多，导致工作效率低，耗时耗试剂，时间和财务成本高，样本量大很容易产生交叉污染。因此，选择直扩成为一种趋势，而不经过核酸提取，样本中存在很多抑制扩增的物质，导致扩增不能正常进行，常出现假阴性等结果。为此，提高扩增试剂的耐抑制物效力成为分子生物学行业的热门研究方向，主要是对Taq DNA聚合酶的改造方面。
Taq DNA聚合酶的编码基因全长2496个碱基，编码832个氨基酸，全酶共分为三个结构域，Taq DNA聚合酶蛋白多肽链N端1-291个氨基酸构成第一个结构域，该结构域表达5’-3’核酸外切酶活性；肽链C端424-832个氨基酸构成第二个结构域，该结构域表达5’-3’聚合酶活性；位于肽链中间的292-423个氨基酸构成第三个结构域，该区域与Taq DNA聚合酶的三维空间结构相关。
酶的改造和修饰主要有以下方法：基因突变、基因融合、化学修饰、抗体修饰和核酸适配体修饰等。其中在提高耐抑制能力上，主要采用基因突变方法，已经被报告的突变位点很多，如：E189K、E230K、E507K、H28R、L30R、G38R、H75R、E76G、E76K、E90K、E734K、E734G、D732G、E708Q、E681M、Q680R、H676R、D578N、I553V等。针对耐抑制物的突变，如：E189K、E230K和E507K可提高Taq DNA聚合酶对SYBR Green Ⅰ dye、全血、SDS和盐酸胍等的耐受能力；D452N、D551N可增强酶对肝素的耐受能力；E708Q可提供酶对SYBR Green Ⅰ dye、全血和土壤的耐受能力。从已被报道的突变可知，绝大多数突变位点设置在第一结构域和第二结构域，通过影响5’-3’核酸外切酶活性和5’-3’聚合酶活性相关的性能来实现Taq DNA聚合酶的改变。
抑制物主要通过干扰细胞的裂解过程、融合或降低核酸或者抑制DNA聚合酶的活性等方面来影响扩增反应，其中多数以抑制DNA聚合酶的活性为主。血液中的抑制物，如：血红蛋白、乳铁蛋白等，是通过让Taq DNA聚合酶失活或者抑制其活性，或者捕获/降解模板DNA和引物，从而抑制扩增。目前很久研究都是在第一结构域和第二结构域进行基因突变，筛选能够提高全血耐受能力的突变体，几乎没有关于第三结构域的突变，对第三结构域的研究具有重要意义。
发明内容
本发明的目的提供Taq DNA聚合酶突变体及其在PCR领域的应用，本发明所述的Taq DNA聚合酶突变体是通过对Taq DNA聚合酶第三结构域进行突变的突变体。
本发明的目的可以通过以下措施达到：
本发明提供一种突变型Taq DNA聚合酶，其特征在于，所述突变体在SEQ ID NO.1所示的序列中，具有下述的一个或多个氨基酸位置上的氨基酸取代，各取代用三联体表示：字母-数字-字母，其中数字表示突变氨基酸的位置，数字前的字母对应突变涉及的氨基酸，数字后的字母表示用于置换数字前氨基酸的氨基酸：T386A，A407L，F413Y。
本发明通过筛选Taq DNA聚合酶第三结构域的突变体，在第三结构域发现了三个有意义的突变位点，分别为：T386A(苏氨酸突变成丙氨酸)、A407L(丙氨酸突变成亮氨酸)、F413Y(苯丙氨酸突变成络氨酸)。我们发现，三个位点同时突变或者两两突变，得到的突变体可以在血液直扩中有很好的扩增性能，具体表现出：耐受血液抑制的能力很强，产量高等方面。
在本发明的一种具体的实施例中，本发明所述的突变型Taq DNA聚合酶Taq-Mut，其特征在于，氨基酸序列如SEQ ID NO.2、SEQ ID NO.3、SEQ ID NO.4或SEQ ID NO.5所示，或与所示序列具有80％同一性的具有Taq DNA聚合酶活性的氨基酸序列；优选的具有85％同一性，更优选的具有90％同一性，最优选的，具有95％同一性，进一步优选，具有99％同一性。
本发明还提供了编码所述的突变型Taq DNA聚合酶的核苷酸序列。
在本发明的一种具体的实施方式中，编码所述的突变型Taq DNA聚合酶的核苷酸序列，如SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9或SEQ ID NO.10所示。需要说明的是，由于同一氨基酸可能有多种不同的密码子来决定，所以编码上述突变型Taq DNA聚合酶Taq-Mut的核苷酸序列也可以是由SEQ ID NO.6所示野生型Taq DNA聚合酶核苷酸序列突变一个或多个核苷酸形成同义突变得到同样可编码本发明所述突变型Taq DNA聚合酶的氨基酸序列的核苷酸序列。也可以是SEQ ID NO.7、SEQ ID NO.8、SEQ ID NO.9或SEQ ID NO.10的同义序列。
本发明还提供一种包含本发明所述的核苷酸序列的重组载体。
本发明还包含一种重组细胞，包含本发明所述的核苷酸序列或重组载体。
本发明还提供本发明所述的突变型Taq DNA聚合酶、本发明所述的核苷酸序列、本发明所述的重组载体或本发明所述的重组细胞在生物技术领域中的应用。
本发明还提供本发明所述的突变型Taq DNA聚合酶、本发明所述的核苷酸序列、本发明所述的重组载体或本发明所述的重组细胞在PCR领域中的应用。
本发明还提供本发明所述的突变型Taq DNA聚合酶、本发明所述的核苷酸序列、本发明所述的重组载体或本发明所述的重组细胞在包含血液的样品的PCR领域中的应用。
在本发明的一种实施例中，包含血液的样品中血液体积浓度可以为10％～40％，发明人发现，本发明所述的突变型Taq DNA聚合酶对血液的耐受性很好，可以优选的在血液体积浓度为30％～40％的样品中进行PCR扩增，更优选的，血液体积浓度为30％的样品中进行PCR扩增。
本发明的有益效果：
本发明所述的突变体，可以通过改变酶的构象，提高酶的耐受能力，很好的应用于血液样本的扩增。本发明所述的突变型Taq DNA聚合酶的酶活虽然没有增强，但其在扩增含高浓度血液样本时，却表现出很好的扩增性能。因此我们推测：从第三结构域中筛选出的T386A(苏氨酸突变成丙氨酸)、A407L(丙氨酸突变成亮氨酸)、F413Y(苯丙氨酸突变成络氨酸)突变，是从结构上改变了Taq DNA聚合酶，是能改变Taq DNA聚合酶构象的突变体，使得原先能被抑制物封闭的区域结构发生变化，变化后，抑制物不再能封闭该位置，减少或消除抑制物对PCR扩增的抑制。
定义：
基因突变：DNA分子中发生碱基对的替换、增添和缺失，而引起的基因结构的改变，基因突变可以是自发的也可以是诱发的。
第一个结构域：Taq DNA聚合酶蛋白多肽链N端1-291个氨基酸构成第一个结构域，该结构域表达5’-3’核酸外切酶活性。
第二个结构域：肽链C端424-832个氨基酸构成第二个结构域，该结构域表达5’-3’聚合酶活性。
第三个结构域：位于肽链中间的292-423个氨基酸构成第三个结构域，该区域与Taq DNA聚合酶的三维空间结构相关。
血液直扩：不用提取血液中的核酸，直接以血液为模板进行PCR扩增，用来实现核酸检测，血液中的血红蛋白、乳铁蛋白等对PCR具有抑制作用。
附图说明
图1是四种突变体Taq和野生型Taq在不同血液浓度时扩增500bp底物的结果；
图2是四种突变体Taq和野生型Taq在不同血液浓度时扩增1013bp底物的结果；
图3是四种突变体Taq和野生型Taq在不同血液浓度时扩增2000bp底物的结果。
具体实施方式
下面结合实施例对本发明做进一步说明，应当理解，此处所描述的具体实施例仅用以解释本发明，并不用于限定本发明，凡在本发明的构思前提下对本发明制备方法的简单改进都属于本发明的保护范围之内。下面实施例未注明具体条件的实验方法，通常按照本领域的公知手段。下述实施例中所用的试验材料，如无特殊说明，均为自常规生化试剂商店购买得到的。
实施例1四种突变体的获得
按照常规方法使用南京诺唯赞生物科技有限公司的
Max Master Mix(P515)和
Ultra One Step Cloning Kit(C115)对Taq DNA聚合酶(序列如SEQID NO.1所示)进行定点突变，得到突变体，称为：Mut1、Mut2、Mut3和Mut4。
Mut1的突变位点为：T386A、A407L、F413Y(序列如SEQ ID NO.2所示)；
Mut2的突变位点为：T386A、A407L(序列如SEQ ID NO.3所示)；
Mut3的突变位点为：A407L、F413Y(序列如SEQ ID NO.4所示)；
Mut4的突变位点为：T386A、F413Y(序列如SEQ ID NO.5所示)。
用于Mut1点突变的引物如下表1～表2所示：
表1 Mut1引物序列
表2 Mut1的载体和插入片段的扩增方式
| 扩增引物对(P515) | Tm(℃) | |
| Insert-01 | 1-1F+2-1R | 60 |
| Vector-01 | 2-1F+1-1R | 60 |
然后将Insert-01与Vector-01用
Ultra One Step Cloning Kit(C115)进行重组获得Mut1。
用于Mut2点突变的引物如下表3～表4所示：
表3 Mut2引物序列
| 引物名称 | 5’-3’序列 |
| 1-1F | CCAACACCGCCCCCGAGGGGGTG |
| 1-1R | TCGGGGGCGGTGTTGGAAGGGTCCAG |
| 2-2F | GCCCTCCTTTCCGAGAGGCTCTTCGCCAACCTGTGGGGGA |
| 2-2R | GGCGAAGAGCCTCTCGGAAAGGAGGGCCCGCTCCC |
表4 Mut2的载体和插入片段的扩增方式
| 扩增引物对(P515) | Tm(℃) | |
| Insert-02 | 1-1F+2-2R | 60 |
| Vector-02 | 2-2F+1-1R | 60 |
然后将Insert-02与Vector-02用
Ultra One Step Cloning Kit(C115)进行重组获得Mut2。
用于Mut3点突变的引物如下表5～表6所示：
表5 Mut3引物序列
| 引物名称 | 5’-3’序列 |
| 2-1F | GCCCTCCTTTCCGAGAGGCTCTACGCCAACCTGTGGGGGA |
| 2-1R | GGCGTAGAGCCTCTCGGAAAGGAGGGCCCGCTCCC |
表6 Mut3的扩增方式
| 扩增引物对(P515) | Tm(℃) | |
| Insert-03 | 2-1F+1-1R | 60 |
然后将Insert-03用
Ultra One Step Cloning Kit(C115)进行重组获得Mut3。
用于Mut4点突变的引物如下表7～表8所示：
表7 Mut4引物序列
表8 Mut4的载体和插入片段的扩增方式
| 扩增引物对(P515) | Tm(℃) | |
| Insert-04 | 1-1F+2-3R | 60 |
| Vector-04 | 2-3F+1-1R | 60 |
然后将Insert-04与Vector-04用
Ultra One Step Cloning Kit(C115)进行重组获得Mut4。
野生型的Taq DNA聚合酶突变前的核酸序列如SEQ ID NO.6所示，突变后的核酸序列如SEQ ID NO.7(Mut1)、SEQ ID NO.8(Mut2)、SEQ ID NO.9(Mut3)、SEQ ID NO.10(Mut4)所示。
实施例2四种突变体Taq具有较高的血液耐受能力
野生型的Taq和四个突变体，按照以下配方，配制成2×PCR Mix，得到五种2×PCRMix。
2×PCR Mix1：200mM Tris-HCl，100mM KCl，0.8mM dNTP，4mM MgCl2，0.2U/μlTaq；
2×PCR Mix2：200mM Tris-HCl，100mM KCl，0.8mM dNTP，4mM MgCl2，0.2U/μlMut1；
2×PCR Mix3：200mM Tris-HCl，100mM KCl，0.8mM dNTP，4mM MgCl2，0.2U/μlMut2；
2×PCR Mix4：200mM Tris-HCl，100mM KCl，0.8mM dNTP，4mM MgCl2，0.2U/μlMut3；
2×PCR Mix5：200mM Tris-HCl，100mM KCl，0.8mM dNTP，4mM MgCl2，0.2U/μlMut4。
五种2×PCR Mix按照以下表20方式混样(50μl反应体系)，为了控制每个孔中模板的投入量一致，以λDNA为模板，加入的血液作为杂质，用以验证血液耐受程度。
表9 PCR反应体系混样方式
| 组分 | 体积 |
| 2×PCR Mix1/2/3/4/5 | 25μl |
| 10M引物 | 各2μl |
| λDNA | 5ng |
| 血液 | 0/5/10/15μl |
| H<sub>2</sub>O | To 50μl |
用于测试的三对引物序列如下表10：
表10测试体系引物序列
反应程序如下表11：
表11 PCR反应程序
1％的琼脂糖凝胶跑核酸电泳，得到如图1(500bp)、图2(1013bp)、图3(2000bp)所示结果，图中Taq-WT是野生型Taq的扩增结果，Mut1、Mut2、Mut3、Mut4是四个突变体酶的扩增结果。0％表示反应体系中不含血液，10％表示反应体系中含10％的血液(50μl反应体系中含5μl血液)，20％表示反应体系中含20％的血液(50μl反应体系中含10μl血液)，30％表示反应体系中含30％的血液(50μl反应体系中含15μl血液)。图1(500bp)、图2(1013bp)、图3(2000bp)中的Marker是DL5000。
从图1(500bp)、图2(1013bp)、图3(2000bp)可以得知：与野生型Taq相比，Mut2、Mut3、Mut4在3个测试体系中均具有更好的扩增性能，Mut1的扩增性能最好，在血液含量高达30％依然扩增很好。
实施例3检测四种突变体和野生型Taq的酶活
将实施例2制备的5种2×PCR Mix用本领域常规方法进行酶活检测，得到结果如表12所示。
表12 5种2×PCR Mix的酶活检测结果(酶活，单位：mU/μl)
| 酶种类 | 重复一 | 重复二 | 重复三 | 平均值 |
| 2×PCR Mix1 | 192 | 190 | 188 | 190 |
| 2×PCR Mix2 | 195 | 183 | 190 | 189 |
| 2×PCR Mix3 | 184 | 191 | 183 | 186 |
| 2×PCR Mix4 | 190 | 187 | 192 | 190 |
| 2×PCR Mix5 | 183 | 197 | 190 | 190 |
由表12的数据可知，突变体酶的酶活并没有增强，而其在扩增含血液样本时，表现出很好的扩增性能。因此结合实施例2的结果我们推测：从第三结构域中筛选出的T386A(苏氨酸突变成丙氨酸)、A407L(丙氨酸突变成亮氨酸)、F413Y(苯丙氨酸突变成络氨酸)突变，可以通过改变酶的构象，提高酶的耐受能力，因此可以很好的应用于血液样本的扩增。
序列表
<110> 南京诺唯赞生物科技股份有限公司
<120> 一种Taq DNA聚合酶突变体Mut2及其应用
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 832
<212> PRT
<213> 水生栖热菌(Thermus aquaticus)
<400> 1
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 2
<211> 832
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Ala Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Leu Leu Ser Glu Arg Leu Tyr Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 3
<211> 832
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Ala Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Leu Leu Ser Glu Arg Leu Phe Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 4
<211> 832
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Thr Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Leu Leu Ser Glu Arg Leu Tyr Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 5
<211> 832
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Met Arg Gly Met Leu Pro Leu Phe Glu Pro Lys Gly Arg Val Leu Leu
1 5 10 15
Val Asp Gly His His Leu Ala Tyr Arg Thr Phe His Ala Leu Lys Gly
20 25 30
Leu Thr Thr Ser Arg Gly Glu Pro Val Gln Ala Val Tyr Gly Phe Ala
35 40 45
Lys Ser Leu Leu Lys Ala Leu Lys Glu Asp Gly Asp Ala Val Ile Val
50 55 60
Val Phe Asp Ala Lys Ala Pro Ser Phe Arg His Glu Ala Tyr Gly Gly
65 70 75 80
Tyr Lys Ala Gly Arg Ala Pro Thr Pro Glu Asp Phe Pro Arg Gln Leu
85 90 95
Ala Leu Ile Lys Glu Leu Val Asp Leu Leu Gly Leu Ala Arg Leu Glu
100 105 110
Val Pro Gly Tyr Glu Ala Asp Asp Val Leu Ala Ser Leu Ala Lys Lys
115 120 125
Ala Glu Lys Glu Gly Tyr Glu Val Arg Ile Leu Thr Ala Asp Lys Asp
130 135 140
Leu Tyr Gln Leu Leu Ser Asp Arg Ile His Val Leu His Pro Glu Gly
145 150 155 160
Tyr Leu Ile Thr Pro Ala Trp Leu Trp Glu Lys Tyr Gly Leu Arg Pro
165 170 175
Asp Gln Trp Ala Asp Tyr Arg Ala Leu Thr Gly Asp Glu Ser Asp Asn
180 185 190
Leu Pro Gly Val Lys Gly Ile Gly Glu Lys Thr Ala Arg Lys Leu Leu
195 200 205
Glu Glu Trp Gly Ser Leu Glu Ala Leu Leu Lys Asn Leu Asp Arg Leu
210 215 220
Lys Pro Ala Ile Arg Glu Lys Ile Leu Ala His Met Asp Asp Leu Lys
225 230 235 240
Leu Ser Trp Asp Leu Ala Lys Val Arg Thr Asp Leu Pro Leu Glu Val
245 250 255
Asp Phe Ala Lys Arg Arg Glu Pro Asp Arg Glu Arg Leu Arg Ala Phe
260 265 270
Leu Glu Arg Leu Glu Phe Gly Ser Leu Leu His Glu Phe Gly Leu Leu
275 280 285
Glu Ser Pro Lys Ala Leu Glu Glu Ala Pro Trp Pro Pro Pro Glu Gly
290 295 300
Ala Phe Val Gly Phe Val Leu Ser Arg Lys Glu Pro Met Trp Ala Asp
305 310 315 320
Leu Leu Ala Leu Ala Ala Ala Arg Gly Gly Arg Val His Arg Ala Pro
325 330 335
Glu Pro Tyr Lys Ala Leu Arg Asp Leu Lys Glu Ala Arg Gly Leu Leu
340 345 350
Ala Lys Asp Leu Ser Val Leu Ala Leu Arg Glu Gly Leu Gly Leu Pro
355 360 365
Pro Gly Asp Asp Pro Met Leu Leu Ala Tyr Leu Leu Asp Pro Ser Asn
370 375 380
Thr Ala Pro Glu Gly Val Ala Arg Arg Tyr Gly Gly Glu Trp Thr Glu
385 390 395 400
Glu Ala Gly Glu Arg Ala Ala Leu Ser Glu Arg Leu Tyr Ala Asn Leu
405 410 415
Trp Gly Arg Leu Glu Gly Glu Glu Arg Leu Leu Trp Leu Tyr Arg Glu
420 425 430
Val Glu Arg Pro Leu Ser Ala Val Leu Ala His Met Glu Ala Thr Gly
435 440 445
Val Arg Leu Asp Val Ala Tyr Leu Arg Ala Leu Ser Leu Glu Val Ala
450 455 460
Glu Glu Ile Ala Arg Leu Glu Ala Glu Val Phe Arg Leu Ala Gly His
465 470 475 480
Pro Phe Asn Leu Asn Ser Arg Asp Gln Leu Glu Arg Val Leu Phe Asp
485 490 495
Glu Leu Gly Leu Pro Ala Ile Gly Lys Thr Glu Lys Thr Gly Lys Arg
500 505 510
Ser Thr Ser Ala Ala Val Leu Glu Ala Leu Arg Glu Ala His Pro Ile
515 520 525
Val Glu Lys Ile Leu Gln Tyr Arg Glu Leu Thr Lys Leu Lys Ser Thr
530 535 540
Tyr Ile Asp Pro Leu Pro Asp Leu Ile His Pro Arg Thr Gly Arg Leu
545 550 555 560
His Thr Arg Phe Asn Gln Thr Ala Thr Ala Thr Gly Arg Leu Ser Ser
565 570 575
Ser Asp Pro Asn Leu Gln Asn Ile Pro Val Arg Thr Pro Leu Gly Gln
580 585 590
Arg Ile Arg Arg Ala Phe Ile Ala Glu Glu Gly Trp Leu Leu Val Ala
595 600 605
Leu Asp Tyr Ser Gln Ile Glu Leu Arg Val Leu Ala His Leu Ser Gly
610 615 620
Asp Glu Asn Leu Ile Arg Val Phe Gln Glu Gly Arg Asp Ile His Thr
625 630 635 640
Glu Thr Ala Ser Trp Met Phe Gly Val Pro Arg Glu Ala Val Asp Pro
645 650 655
Leu Met Arg Arg Ala Ala Lys Thr Ile Asn Phe Gly Val Leu Tyr Gly
660 665 670
Met Ser Ala His Arg Leu Ser Gln Glu Leu Ala Ile Pro Tyr Glu Glu
675 680 685
Ala Gln Ala Phe Ile Glu Arg Tyr Phe Gln Ser Phe Pro Lys Val Arg
690 695 700
Ala Trp Ile Glu Lys Thr Leu Glu Glu Gly Arg Arg Arg Gly Tyr Val
705 710 715 720
Glu Thr Leu Phe Gly Arg Arg Arg Tyr Val Pro Asp Leu Glu Ala Arg
725 730 735
Val Lys Ser Val Arg Glu Ala Ala Glu Arg Met Ala Phe Asn Met Pro
740 745 750
Val Gln Gly Thr Ala Ala Asp Leu Met Lys Leu Ala Met Val Lys Leu
755 760 765
Phe Pro Arg Leu Glu Glu Met Gly Ala Arg Met Leu Leu Gln Val His
770 775 780
Asp Glu Leu Val Leu Glu Ala Pro Lys Glu Arg Ala Glu Ala Val Ala
785 790 795 800
Arg Leu Ala Lys Glu Val Met Glu Gly Val Tyr Pro Leu Ala Val Pro
805 810 815
Leu Glu Val Glu Val Gly Ile Gly Glu Asp Trp Leu Ser Ala Lys Glu
820 825 830
<210> 6
<211> 2499
<212> DNA
<213> 水生栖热菌(Thermus aquaticus)
<400> 6
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccacccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccgc cctttccgag aggctcttcg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggaatga 2499
<210> 7
<211> 2499
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccgcccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccct cctttccgag aggctctacg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggaatga 2499
<210> 8
<211> 2499
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccgcccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccct cctttccgag aggctcttcg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggaatga 2499
<210> 9
<211> 2499
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccacccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccct cctttccgag aggctctacg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggaatga 2499
<210> 10
<211> 2499
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
atgaggggga tgctgcccct ctttgagccc aagggccggg tcctcctggt ggacggccac 60
cacctggcct accgcacctt ccacgccctg aagggcctca ccaccagccg gggggagccg 120
gtgcaggcgg tctacggctt cgccaagagc ctcctcaagg ccctcaagga ggacggggac 180
gcggtgatcg tggtctttga cgccaaggcc ccctccttcc gccacgaggc ctacgggggg 240
tacaaggcgg gccgggcccc cacgccggag gactttcccc ggcaactcgc cctcatcaag 300
gagctggtgg acctcctggg gctggcgcgc ctcgaggtcc cgggctacga ggcggacgac 360
gtcctggcca gcctggccaa gaaggcggaa aaggagggct acgaggtccg catcctcacc 420
gccgacaaag acctttacca gctcctttcc gaccgcatcc acgccctcca ccccgagggg 480
tacctcatca ccccggcctg gctttgggaa aagtacggcc tgaggcccga ccagtgggcc 540
gactaccggg ccctgaccgg ggacgagtcc gacaaccttc ccggggtcaa gggcatcggg 600
gagaagacgg cgaggaagct tctggaggag tgggggagcc tggaagccct cctcaagaac 660
ctggaccggc tgaagcccgc catccgggag aagatcctgg cccacatgga cgatctgaag 720
ctctcctggg acctggccaa ggtgcgcacc gacctgcccc tggaggtgga cttcgccaaa 780
aggcgggagc ccgaccggga gaggcttagg gcctttctgg agaggcttga gtttggcagc 840
ctcctccacg agttcggcct tctggaaagc cccaaggccc tggaggaggc cccctggccc 900
ccgccggaag gggccttcgt gggctttgtg ctttcccgca aggagcccat gtgggccgat 960
cttctggccc tggccgccgc cagggggggc cgggtccacc gggcccccga gccttataaa 1020
gccctcaggg acctgaagga ggcgcggggg cttctcgcca aagacctgag cgttctggcc 1080
ctgagggaag gccttggcct cccgcccggc gacgacccca tgctcctcgc ctacctcctg 1140
gacccttcca acaccgcccc cgagggggtg gcccggcgct acggcgggga gtggacggag 1200
gaggcggggg agcgggccgc cctttccgag aggctctacg ccaacctgtg ggggaggctt 1260
gagggggagg agaggctcct ttggctttac cgggaggtgg agaggcccct ttccgctgtc 1320
ctggcccaca tggaggccac gggggtgcgc ctggacgtgg cctatctcag ggccttgtcc 1380
ctggaggtgg ccgaggagat cgcccgcctc gaggccgagg tcttccgcct ggccggccac 1440
cccttcaacc tcaactcccg ggaccagctg gaaagggtcc tctttgacga gctagggctt 1500
cccgccatcg gcaagacgga gaagaccggc aagcgctcca ccagcgccgc cgtcctggag 1560
gccctccgcg aggcccaccc catcgtggag aagatcctgc agtaccggga gctcaccaag 1620
ctgaagagca cctacattga ccccttgccg gacctcatcc accccaggac gggccgcctc 1680
cacacccgct tcaaccagac ggccacggcc acgggcaggc taagtagctc cgatcccaac 1740
ctccagaaca tccccgtccg caccccgctt gggcagagga tccgccgggc cttcatcgcc 1800
gaggaggggt ggctattggt ggccctggac tatagccaga tagagctcag ggtgctggcc 1860
cacctctccg gcgacgagaa cctgatccgg gtcttccagg aggggcggga catccacacg 1920
gagaccgcca gctggatgtt cggcgtcccc cgggaggccg tggaccccct gatgcgccgg 1980
gcggccaaga ccatcaactt cggggtcctc tacggcatgt cggcccaccg cctctcccag 2040
gagctagcca tcccttacga ggaggcccag gccttcattg agcgctactt tcagagcttc 2100
cccaaggtgc gggcctggat tgagaagacc ctggaggagg gcaggaggcg ggggtacgtg 2160
gagaccctct tcggccgccg ccgctacgtg ccagacctag aggcccgggt gaagagcgtg 2220
cgggaggcgg ccgagcgcat ggccttcaac atgcccgtcc agggcaccgc cgccgacctc 2280
atgaagctgg ctatggtgaa gctcttcccc aggctggagg aaatgggggc caggatgctc 2340
cttcaggtcc acgacgagct ggtcctcgag gccccaaaag agagggcgga ggccgtggcc 2400
cggctggcca aggaggtcat ggagggggtg tatcccctgg ccgtgcccct ggaggtggag 2460
gtggggatag gggaggactg gctctccgcc aaggaatga 2499
Claims (7)
1.一种突变型Taq DNA聚合酶，其特征在于，氨基酸序列如SEQ ID NO.3所示。
2.编码权利要求1所述的突变型Taq DNA聚合酶的核苷酸序列。
3.编码权利要求1所述的突变型Taq DNA聚合酶的核苷酸序列，如SEQ ID NO.8。
4.一种包含权利要求2或3所述的核苷酸序列的重组载体。
5.一种重组细胞，包含权利要求2或3所述的核苷酸序列或权利要求4所述的重组载体。
6.权利要求1所述的突变型Taq DNA聚合酶、权利要求2或3所述的核苷酸序列、权利要求4所述的重组载体、权利要求5所述的重组细胞在PCR领域中的应用。
7.权利要求1所述的突变型Taq DNA聚合酶、权利要求2或3所述的核苷酸序列、权利要求4所述的重组载体、权利要求5所述的重组细胞在包含血液的样品的PCR领域中的应用，所述样品中血液体积浓度为10%～30%。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010982425.2A CN112080482B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut2及其应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010982425.2A CN112080482B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut2及其应用 |
| CN201911038688.1A CN110747183B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911038688.1A Division CN110747183B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112080482A CN112080482A (zh) | 2020-12-15 |
| CN112080482B true CN112080482B (zh) | 2021-04-20 |
Family
ID=69280857
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010982425.2A Active CN112080482B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut2及其应用 |
| CN202010980814.1A Active CN112029748B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut4及其应用 |
| CN201911038688.1A Active CN110747183B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体及其应用 |
| CN202010980819.4A Active CN112029749B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut3及其应用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010980814.1A Active CN112029748B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut4及其应用 |
| CN201911038688.1A Active CN110747183B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体及其应用 |
| CN202010980819.4A Active CN112029749B (zh) | 2019-10-29 | 2019-10-29 | 一种Taq DNA聚合酶突变体Mut3及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN112080482B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111690626B (zh) * | 2020-07-02 | 2021-03-26 | 南京诺唯赞生物科技股份有限公司 | 一种融合型Taq DNA聚合酶及其制备方法和应用 |
| CN111560073B (zh) * | 2020-07-16 | 2020-10-09 | 翌圣生物科技（上海）有限公司 | Taq酶5’-3’聚合酶活性封闭单克隆抗体及其应用 |
| CN112725299B (zh) * | 2020-12-30 | 2023-10-10 | 苏州白垩纪生物科技有限公司 | 改善Taq DNA聚合酶耐受性的突变体及制备方法和应用 |
| CN113373127B (zh) * | 2021-03-30 | 2022-10-04 | 中国农业科学院生物技术研究所 | Taq DNA聚合酶突变体及其应用 |
| CN116200363A (zh) * | 2021-11-30 | 2023-06-02 | 广州达安基因股份有限公司 | Taq酶突变体、其制备方法和应用 |
| CN115261351B (zh) * | 2022-06-08 | 2024-03-29 | 厦门通灵生物医药科技有限公司 | 一种逆转录-聚合双功能酶及其制备方法、应用 |
| CN114958800B (zh) * | 2022-06-24 | 2023-08-25 | 北京脉道生物药品制造有限公司 | 一种耐受血液或者血液制品抑制的Taq DNA聚合酶突变体及其应用 |
| CN117487775B (zh) * | 2024-01-02 | 2024-03-22 | 深圳市检验检疫科学研究院 | 一种高酶活的Taq DNA聚合酶及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011014885A1 (en) * | 2009-07-31 | 2011-02-03 | Agilent Technologies, Inc. | Thermostable type-a dna polymerase mutants with increased polymerization rate and resistance to inhibitors |
| CN104845950A (zh) * | 2014-02-14 | 2015-08-19 | 安捷伦科技有限公司 | 对血液中抑制剂具有增加的抗性的热稳定性a型dna聚合酶突变体 |
| CN105907734A (zh) * | 2016-04-25 | 2016-08-31 | 天根生化科技（北京）有限公司 | Taq DNA聚合酶、PCR反应液及其应用 |
| CN108118038A (zh) * | 2016-11-28 | 2018-06-05 | 青岛蔚蓝生物集团有限公司 | 一种葡萄糖氧化酶突变体 |
| CN108265039A (zh) * | 2016-12-30 | 2018-07-10 | 天津强微特生物科技有限公司 | 一种突变TaqDNA聚合酶及其纯化方法 |
| CN109251907A (zh) * | 2017-07-12 | 2019-01-22 | 基因凯斯特有限公司 | 基因突变特异性扩增效率提高的dna聚合酶 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300073B1 (en) * | 1999-10-01 | 2001-10-09 | Clontech Laboratories, Inc. | One step RT-PCR methods, enzyme mixes and kits for use in practicing the same |
| US10457968B2 (en) * | 2008-11-03 | 2019-10-29 | Kapa Biosystems, Inc. | Modified type A DNA polymerases |
| EP3109326B1 (en) * | 2010-06-21 | 2022-01-12 | Life Technologies Corporation | Composition and method for nucleic acid synthesis and amplification using rt |
| EP2582850B1 (en) * | 2010-06-21 | 2016-11-09 | Life Technologies Corporation | Compositions, kits, and methods for synthesis and/or detection of nucleic acids |
| GB201113430D0 (en) * | 2011-08-03 | 2011-09-21 | Fermentas Uab | DNA polymerases |
| CN103509767B (zh) * | 2012-06-27 | 2016-08-03 | 菲鹏生物股份有限公司 | 一种突变型Taq酶及其制备方法 |
| WO2016183294A1 (en) * | 2015-05-12 | 2016-11-17 | Dna Polymerase Technology, Inc. | Mutant polymerases and uses thereof |
| CN105039278B (zh) * | 2015-06-17 | 2018-09-11 | 菲鹏生物股份有限公司 | 突变型Taq DNA聚合酶及其制备方法和应用 |
| CN106754812B (zh) * | 2016-12-21 | 2019-03-19 | 南京诺唯赞生物科技有限公司 | 一种可提高加A效率的突变型Taq酶及其制备方法和应用 |
| CN108130318B (zh) * | 2018-02-28 | 2020-07-14 | 深圳市艾伟迪生物科技有限公司 | 突变型Taq DNA聚合酶、免核酸提取直接PCR扩增的试剂盒及其应用 |
| CN109402082A (zh) * | 2018-11-26 | 2019-03-01 | 南京诺唯赞生物科技有限公司 | 一种Taq DNA聚合酶突变体及其应用 |
-
2019
- 2019-10-29 CN CN202010982425.2A patent/CN112080482B/zh active Active
- 2019-10-29 CN CN202010980814.1A patent/CN112029748B/zh active Active
- 2019-10-29 CN CN201911038688.1A patent/CN110747183B/zh active Active
- 2019-10-29 CN CN202010980819.4A patent/CN112029749B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011014885A1 (en) * | 2009-07-31 | 2011-02-03 | Agilent Technologies, Inc. | Thermostable type-a dna polymerase mutants with increased polymerization rate and resistance to inhibitors |
| CN104845950A (zh) * | 2014-02-14 | 2015-08-19 | 安捷伦科技有限公司 | 对血液中抑制剂具有增加的抗性的热稳定性a型dna聚合酶突变体 |
| CN105907734A (zh) * | 2016-04-25 | 2016-08-31 | 天根生化科技（北京）有限公司 | Taq DNA聚合酶、PCR反应液及其应用 |
| CN108118038A (zh) * | 2016-11-28 | 2018-06-05 | 青岛蔚蓝生物集团有限公司 | 一种葡萄糖氧化酶突变体 |
| CN108265039A (zh) * | 2016-12-30 | 2018-07-10 | 天津强微特生物科技有限公司 | 一种突变TaqDNA聚合酶及其纯化方法 |
| CN109251907A (zh) * | 2017-07-12 | 2019-01-22 | 基因凯斯特有限公司 | 基因突变特异性扩增效率提高的dna聚合酶 |
Non-Patent Citations (7)
| Title |
|---|
| Direct DNA Amplification from Crude Clinical Samples Using a PCR Enhancer Cocktail and Novel Mutants of Taq;Zhian Zhang等;《Journal of Molecular Diagnostics》;20100331;第12卷(第2期);152-161 * |
| DNA polymerase [Thermus aquaticus];Lawyer,F.C.等;《Genbank database》;19930426;accession NO:AAA27507.1 * |
| Mutant Taq DNA polymerases with improved elongation ability as a useful reagent for genetic engineering;Takeshi Yamagami等;《Frontiers in Microbiology》;20140903;第5卷(第1期);461 * |
| Mutants of Taq DNA polymerase resistant to PCR inhibitors allow DNA amplification from whole blood and crude soil samples;Milko B. Kermekchiev等;《Nucleic Acids Research》;20090210;第37卷(第5期);e40 * |
| Taq DNA聚合酶的改造及应用;林晴;《中国优秀硕士学位论文全文数据库（电子期刊）基础科学辑》;20080715(第07期);A006-47 * |
| Taq DNA聚合酶的结构修饰与表征;郭佳;《中国优秀硕士学位论文全文数据库（电子期刊）基础科学辑》;20140815(第08期);A006-105 * |
| 优化反应体系提升Phanta DNA 聚合酶对非处理标本的检测性能;陈振华等;《生物加工过程》;20080315;第16卷(第2期);102-108 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112080482A (zh) | 2020-12-15 |
| CN110747183A (zh) | 2020-02-04 |
| CN112029748B (zh) | 2021-03-23 |
| CN112029749B (zh) | 2021-05-04 |
| CN112029748A (zh) | 2020-12-04 |
| CN110747183B (zh) | 2020-10-23 |
| CN112029749A (zh) | 2020-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112080482B (zh) | 一种Taq DNA聚合酶突变体Mut2及其应用 | |
| CN110684752B (zh) | 一种耐受性提高的突变型Taq DNA聚合酶及其制备方法和应用 | |
| CN108130318B (zh) | 突变型Taq DNA聚合酶、免核酸提取直接PCR扩增的试剂盒及其应用 | |
| CN108070577B (zh) | 一种抗血清干扰TaqDNA聚合酶及其制备和应用 | |
| CN108473970B (zh) | Dna聚合酶变体 | |
| EP2582808B1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| CN108350087A (zh) | Dna聚合酶变体 | |
| JP2020036614A (ja) | 核酸増幅法 | |
| CN109266628B (zh) | 一种融合的TaqDNA聚合酶及其应用 | |
| US10023850B2 (en) | DNA polymerases with increased 3′-mismatch discrimination | |
| US20140342409A1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| WO2012110060A1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| CN113186175B (zh) | 突变型Taq DNA聚合酶、编码DNA序列、重组载体、重组表达细胞及其应用 | |
| CN113388595B (zh) | 高效末端加A的突变型Taq DNA聚合酶及其编码DNA | |
| EP2582805B1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| EP2582801B1 (en) | Dna polymerases with increased 3'-mismatch discrimination | |
| CN114438053A (zh) | 一种dna聚合酶突变体及其应用 | |
| US9765311B2 (en) | DNA polymerases with increased 3′-mismatch discrimination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |